Maltby N, Broe G A, Creasey H, Jorm A F, Christensen H, Brooks W S
University of Sydney, Department of Geriatric Medicine, Repatriation General Hospital, Concord, Australia.
BMJ. 1994 Apr 2;308(6933):879-83. doi: 10.1136/bmj.308.6933.879.
To assess the efficacy of tacrine and lecithin in treating Alzheimer's disease over nine months.
Double blind randomised controlled trial.
Outpatients clinic of university department of geriatric medicine.
53 subjects (26 women, 27 men) with probable Alzheimer's disease. 41 completed the dose finding phase and were randomised to treatment. 32 (14 tacrine, 18 placebo) completed nine months' treatment.
Lecithin and tacrine or lecithin and placebo for 36 weeks.
Scores on neuropsychological tests sensitive to deficits in the cholinergic system; mini-mental state score; behaviour change; mood; functional state; and stress in carers.
The tacrine and placebo groups were similar except that the tacrine group had a longer duration of disease (mean 5.4 v 2.5 years in placebo group; P = 0.003). Only 17 of the 32 patients could tolerate the maximum dose of tacrine (100 mg). No significant difference was found between the groups for any of the tests after nine months' treatment except for the digit backwards test, which is insensitive to cholinergic deficit. Analysis of subjects taking the maximum dose of tacrine and of subjects with mild dementia also found no differences.
Tacrine produces no clinically relevant improvement over 36 weeks at the doses tolerated by these patients.
评估他克林和卵磷脂治疗阿尔茨海默病九个月的疗效。
双盲随机对照试验。
大学老年医学科门诊。
53名可能患有阿尔茨海默病的受试者(26名女性,27名男性)。41名完成了剂量探索阶段并被随机分组接受治疗。32名(14名服用他克林,18名服用安慰剂)完成了九个月的治疗。
卵磷脂和他克林或卵磷脂和安慰剂治疗36周。
对胆碱能系统缺陷敏感的神经心理学测试得分;简易精神状态评分;行为改变;情绪;功能状态;以及照顾者的压力。
他克林组和安慰剂组相似,只是他克林组的病程更长(安慰剂组平均病程为2.5年,他克林组为5.4年;P = 0.003)。32名患者中只有17名能够耐受他克林的最大剂量(100毫克)。九个月治疗后,除对胆碱能缺陷不敏感的倒背数字测试外,两组在任何测试中均未发现显著差异。对服用他克林最大剂量的受试者和轻度痴呆受试者的分析也未发现差异。
在这些患者能够耐受的剂量下,他克林在36周内未产生临床上相关的改善。